KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) FCF Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed FCF Margin for 11 consecutive years, with 822.6% as the latest value for Q1 2025.

  • Quarterly FCF Margin changed N/A to 822.6% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 3732.23% through Dec 2025, changed N/A year-over-year, with the annual reading at 3732.23% for FY2025, N/A changed from the prior year.
  • FCF Margin for Q1 2025 was 822.6% at Xenon Pharmaceuticals, up from 23324.24% in the prior quarter.
  • The five-year high for FCF Margin was 212.64% in Q1 2022, with the low at 23324.24% in Q3 2022.
  • Average FCF Margin over 3 years is 3703.67%, with a median of 599.26% recorded in 2021.
  • Peak annual rise in FCF Margin hit 27180bps in 2022, while the deepest fall reached -2298580bps in 2022.
  • Over 3 years, FCF Margin stood at 567.94% in 2021, then tumbled by -4007bps to 23324.24% in 2022, then surged by 96bps to 822.6% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 822.6%, 23324.24%, and 3248.51% for Q1 2025, Q3 2022, and Q2 2022 respectively.